A recent study demonstrated that APS, as an adjuvant, greatly boosted the efficacy of the influenza vaccine, as evidenced by enhanced neutralizing antibody levels, a higher frequency of specific CD8+ cells, and an increased survival rate in influenza-infected mice. The gene discussed is CD8A; the disease is influenza.